Company Overview
Snapshot
Founded in October 2021 by Yogev Debbi and Roy Nevo, Mana.bio operates with 11–50 employees. The company has raised $24.5M across two funding rounds from five investors. In October 2023, Mana.bio secured $19.5M in Seed funding.
Business overview
Mana.bio specializes in AI-based drug delivery solutions, focusing on gene therapy within the Health Tech & Life Sciences sector. The company's core technology integrates machine learning and nanotechnology to develop advanced drug-delivery systems, particularly a platform for lipid nanoparticle development for oligonucleotide therapies, including mRNA-based therapeutics, vaccines, and gene therapy. Mana.bio serves the pharmaceutical and biotechnology industries, operating within the machine learning, nanotechnology, artificial intelligence, genetics, drug-delivery, cell-therapy, and therapeutics categories.
Strategic signal
In September 2025, Mana.bio launched Mina™, an AI agent powered by a large language model specifically designed for lipid nanoparticles. This development signals a significant advancement in leveraging AI for RNA delivery, potentially accelerating the discovery and optimization of targeted therapeutic solutions and demonstrating the company's commitment to innovation in the biotechnology space.
Log in to access full profile ›Company Intelligence Q&A
- When was Mana.bio founded?
- Mana.bio was founded in October 2021 by Yogev Debbi and Roy Nevo.
- What significant product did Mana.bio launch recently?
- In September 2025, Mana.bio unveiled Mina™, the world's first large language model-powered AI agent for lipid nanoparticles, designed to revolutionize RNA delivery.
- What was Mana.bio's most recent funding round?
- In October 2023, Mana.bio raised $19.5M in Seed funding. Investors included Andreessen Horowitz and NFX Capital.
- What is Mana.bio's total capital raised?
- Mana.bio has raised a total of $24.5M across two funding rounds.
- What is Mana.bio's primary focus in drug delivery?
- Mana.bio specializes in AI-based drug delivery solutions, with a particular focus on gene therapy and the development of lipid nanoparticle systems for oligonucleotide therapies, including mRNA-based therapeutics and vaccines.